Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Body Composition Sub-study of the D2EFT Trial

This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will offer …

antiretroviral
lamivudine
dolutegravir
emtricitabine
HIV Vaccine
  • 9 views
  • 21 Feb, 2022
  • 7 locations
E-Health for Zero Infections - Facilitating Access to and Use of HIV Pre-Exposure Prophylaxis (PrEP) in The Netherlands

Offering PrEP care online and reducing the frequency of monitoring may increase access to HIV PrEP. The objective of this study is to assess the non-inferiority of an internet-based HIV PrEP-service and reduced frequency of monitoring visits in comparison to standard-of-care at the Public Health Service in 4 regions in …

HIV Vaccine
pre-exposure prophylaxis (prep)
Accepts healthy volunteers
  • 0 views
  • 01 Nov, 2021
  • 4 locations
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant

This is an open-label study, where participants will be switched from their current HIV medication to the study drug, Biktarvy. Open-label means both the investigator and the participant will know what drug will be given. Participants will be followed for 48 weeks in order to monitor the efficacy, safety and …

HIV Vaccine
tenofovir
immunodeficiency
bictegravir/emtricitabine/tenofovir
biktarvy
  • 0 views
  • 29 Nov, 2021
  • 1 location
Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women

Recent studies have showed that there were significant drug-drug interactions (DDI) from feminizing hormone therapy (FHT) towards emtricitabine/tenofovir disoproxil fumarate (F/TDF)-based pre

Accepts healthy volunteers
  • 0 views
  • 10 May, 2022
  • 1 location
Biomarkers for Event-driven PrEP Adherence

This study aims to recruit 20 participants who will take the combination anti-HIV drug tenofovir+emtricitabine (TDF/FTC) at specified times. Participants will then provide biologic samples for

HIV Vaccine
tenofovir
Accepts healthy volunteers
hepatitis b surface antigen
emtricitabine
  • 1 views
  • 28 Feb, 2022
  • 1 location
Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone (DOLUVOIR)

The main objective of the study is to characterize the diffusion of dolutegravir and associated backbone (abacavir/lamivudine or tenofovir/emtricitabine) in HIV-1 chronic patients in the main

  • 0 views
  • 22 Mar, 2022
  • 1 location
B/F/TAF Switch Study for HIV-HBV Coinfection (BEST-HBV)

The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with

lamivudine
tenofovir
antiretrovirals
emtricitabine
HIV Infection
  • 1 views
  • 25 Mar, 2022
  • 1 location
BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study (BONE:STAR)

contraception. HIV virologically suppressed women on DMPA will be switched from their TDF based regimen to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy) in a randomized fashion. HIV

bone mineral density
antiretroviral therapy
tenofovir
  • 1 views
  • 24 Feb, 2022
  • 1 location
INSTI's For The Management of HIV-associated TB (INSIGHT)

This study is being conducted to assess the antiretroviral activity of a fixed-drug, single tablet, combination of Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir alafenamide 25mg (Biktarvy

  • 0 views
  • 17 Mar, 2022
A Test and Treat Strategy in New HIV Diagnosis.

bictegravir 50 mg + emtricitabine 200 mg + tenofovir alafenamide 25 mg within the first week since the HIV-1 confirmation during 48 weeks.

  • 0 views
  • 23 Dec, 2021
  • 2 locations